Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2500559 | 0.87 | ELANE (0.52) | CA1KMT2AHPGDPREPCA12 | |
| SCHEMBL936407 | 0.85 | MAPT (0.53) | CA1KMT2AHPGDPREPTSHR | |
| SCHEMBL5280416 | 0.84 | ELANE (0.57) | PREPSRD5A2ALDH1A1 | |
| SCHEMBL7291293 | 0.84 | PREP (0.45) | CA1CA2HPGDPREPCA12 | |
| SCHEMBL12339125 | 0.84 | PARP10 (0.53) | CA1CA2KMT2APREPCA12 | |
| SCHEMBL9011038 | 0.83 | KMT2A (0.50) | CA1CA2KMT2AHPGDTP53 | |
| SCHEMBL15779472 | 0.82 | MAPT (0.50) | KMT2APREPHSD17B10PARP10ALDH1A1 | |
| SCHEMBL1604136 | 0.82 | PREP (0.44) | CA1CA2PREPHSD17B10CA12 | |
| SCHEMBL8906116 | 0.82 | CA1 (0.56) | CA1CA2KMT2APREPTSHR | |
| SCHEMBL6763899 | 0.82 | PREP (0.53) | CA1CA2PREPCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| CN-112159373-B | Compound and application thereof in preparation of targeted PTL and/or NPC1L1 inhibition drugs | 青岛大学 | 2023-10-20 | — | — | CN | disclosed |
| US-20220306677-A1 | COMPOSITIONS AND METHODS FOR MAKING HYBRID POLYPEPTIDES | YALE UNIVERSITY | 2022-09-29 | — | — | US | disclosed |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2022-09-29 | — | — | US | disclosed |
| CN-111808059-B | Tumor diagnosis and treatment fluorescent probe targeting tumor Woberg effect | 天津大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-113149930-B | Cell sugar transport channel inhibitor | 天津大学 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022063071-A1 | COMPOUND AND USE THEREOF IN PREPARATION OF DRUG FOR TARGETED INHIBITION OF PTL AND/OR NPC1L1 | 青岛大学 | 2022-03-31 | — | — | WO | disclosed |
| CN-114008025-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2021-01-07 | — | — | US | disclosed |
| CN-112159373-A | Compound and application thereof in preparation of PTL and/or NPC1L1 targeted inhibition drugs | 青岛大学附属医院 | 2021-01-01 | — | — | CN | disclosed |
| US-5830920-A | PREVENTION GROWTH OF SMOOTH MUSCLE CELLS | HOFFMANN-LA ROCHE INC. (US) | 1998-11-03 | — | — | US | disclosed |
| US-5750706-A | TREATMENT OF INFLAMMATORY SKIN DISORDERS AND ALOPECIA | HOFFMANN-LA ROCHE INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5583222-A | ANTIINFLAMMATORY AGENTS FOR TREATMENT OF SKIN DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0741128-A2 | Sulphuric acid esters of sugar alcohols for the inhibition of the migration and proliferation of smooth muscle cells of the vascular walls | F. HOFFMANN-LA ROCHE AG (CH) | 1996-11-06 | — | — | EP | disclosed |
| EP-0654995-B1 | 4-OXA-1-AZABICYCLO (3,2,0) HEPTAN-7-ONE DERIVATIVES AS ANTITUMOR AGENTS | TAIHO PHARMACEUTICAL CO LTD (JP) | 1996-10-23 | — | — | EP | disclosed |
| US-5561126-A | OXAPENAMS HAVING CHEMICAL STABILITY; ANTICARCINOGENIC AGENTS; LEUKEMIA | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-10-01 | — | — | US | disclosed |
| EP-0663393-A1 | Novel 3-amino/hydroxy-4- 4-benzoylphenylcarboxylamino/oxy -azepanes and their homologies as protein kinase inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1995-07-19 | — | — | EP | disclosed |
| EP-0654995-A1 | 4-OXA-1-AZABICYCLO (3,2,0) HEPTAN-7-ONE DERIVATIVES AS ANTITUMOR AGENTS. | TAIHO PHARMACEUTICAL CO LTD (JP) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994001109-A1 | 4-OXA-1-AZABICYCLO [3,2,0] HEPTAN-7-ONE DERIVATIVES AS ANTITUMOR AGENTS | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 1994-01-20 | — | — | WO | disclosed |
| EP-0438873-A1 | Inhibitor of ribonucleotide reductase of herpes viruses | MERCK & CO. INC. (US) | 1991-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306677-A1 | COMPOSITIONS AND METHODS FOR MAKING HYBRID POLYPEPTIDES | NSUN3, TARBP1, TRDMT1 | CA1 2704/4885CA2 3555/4885KMT2A 1954/4885 |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | CA1 4586/4885CA2 3764/4885KMT2A 1780/4885 |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | CA1 634/4885CA2 1483/4885KMT2A 1401/4885 |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | CA1 634/4885CA2 1483/4885KMT2A 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.